{
    "nct_id": "NCT05563766",
    "official_title": "A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer",
    "inclusion_criteria": "* Capable of giving informed consent\n* Pathologic diagnosis of esophageal cancer (ESCC or EAC) or GEJ cancer deemed resectable by a surgeon with a plan to undergo neoadjuvant chemoradiation and curative intent esophagectomy\n* World Health Organization (WHO)/ECOG performance status (PS) of 0-2 at enrollment\n* Adequate renal and liver function as judged by the treating physician\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Inability to provide Informed Consent\n* NYHA class III or IV CHF\n* LFT>3X upper limit of normal\n* Drug allergy to itraconazole\n* Positive pregnancy test\n* Those with QTc>450 ms will have QTc monitored during therapy by serial EKG to ensure QTc does not lengthen to what the treating clinician considers significant",
    "miscellaneous_criteria": ""
}